1394-P: Impact of Finerenone on Albuminuria in Type 1 Diabetes by Baseline HbA1c Levels and Diabetes Duration: An Exploratory Analysis of the FINE-ONE Trial
Randomized trial assesses effect of finerenone on albuminuria in adults with type 1 diabetes, indicating consistent benefits across diabetes duration and HbA1c levels.
Key Points
This analysis explores how finerenone affects albuminuria based on HbA1c levels and duration of diabetes in individuals with type 1 diabetes and chronic kidney disease.
Randomized 1:1 trial of 242 adults with type 1 diabetes and chronic kidney disease on stable ACEi/ARB therapy receiving finerenone or placebo over 6 months.
Primary outcome measured was the change in urinary albumin-to-creatinine ratio (UACR) from baseline.
Participants were stratified by baseline HbA1c tertiles to analyze treatment effects.
Finerenone reduced median UACR from 574.6 to 373.5 mg/g, while placebo reduced it from 506.4 to 475.6 mg/g; p=0.0001 for treatment effect.
No significant difference in UACR reduction was observed across HbA1c levels (p interaction = 0.41) and diabetes duration (p interaction = 0.70).
Hyperkalemia was the most common adverse event, and safety profiles were similar across groups.